Clinical trials: Asthma Patients
Asthma
Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)
Bronchial asthma is among the world's most prevalent diseases. Roflumilast is a novel, orally active, selective enzyme inhibitor (phosphodiesterase 4 inhibitor), which has shown effectiveness in the treatment of asthma.
- Trial name
- NCT00163527
- Testing
- Roflumilast
- Where
- 24 sites in United States, Austria and 22 more
- Volunteers
- 2,054 people
- Sponsor
- AstraZeneca
Asthma
Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium
The purpose of this trial was to demonstrate that the efficacy of two treatment arms of the fixed-dose combination product QVM149 was non-inferior to the efficacy of the free combination arm of salmeterol/ fluticasone+ tiotropium…
- Trial name
- ARGON (NCT03158311)
- Testing
- QVM149, Salmeterol/fluticasone plus tiotropium
- Where
- 163 sites in Argentina, Chile and 18 more
- Volunteers
- 1,426 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma
This Phase II, randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of lebrikizumab on airway eosinophilic inflammation in participants with uncontrolled asthma who are using inhaled…
- Trial name
- NCT02099656
- Testing
- Lebrikizumab, Inhaled corticposteroids (ICS), Second Asthma Controller Medication
- Where
- 28 sites in United States, Canada and 4 more
- Volunteers
- 64 people
- Sponsor
- Hoffmann-La Roche
Asthma
Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma
The purpose of the trial was to evaluate the efficacy and safety of two different doses of QVM149 (QVM149 150/50/80 μg and QVM149 150/50/160 μg via Concept1) over two respective QMF149 doses (QMF149 150/160 μg and QMF149 150/320)…
- Trial name
- NCT02571777
- Testing
- QVM149 150/50/160, QVM149 150/50/80, QMF149 150/320
- Where
- 403 sites in Argentina, Austria and 39 more
- Volunteers
- 3,092 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroids
The aim of this study is to assess and compare efficacy and safety of BI 54903 at medium doses twice daily and high doses once daily (evening dosing) and placebo over an 12-week treatment period in asthmatic patients aged 12 to…
- Trial name
- NCT01458912
- Testing
- BI 54903 MD, BI 54903 HD
- Sponsor
- Boehringer Ingelheim
Asthma
A 3-week Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma
This study is designed to investigate the ability of patients with asthma to properly use a new multi-dose dry powder inhaler (MDDPI) device in a real-life situation.
- Trial name
- NCT00130351
- Testing
- formoterol
- Where
- 12 sites in United States
- Volunteers
- 155 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
A Study to Investigate the Effect of Inhaling Single Doses of Different Formulations of GW642444M in Asthmatic Patients
This study will involve the use of a new medicine called GW642444 being developed for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00702910
- Testing
- GW642444, Magnesium Stearate
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Asthma
Characteristics of Pts Initiating Spiriva Respimat in Asthma
This study is a cross-sectional, non-interventional study based on existing data (NISed).
- Trial name
- NCT03692676
- Testing
- Spiriva Respimat
- Where
- Germany
- Volunteers
- 116,133 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma
This is a Phase 3, randomized, placebo-controlled, double-blind,double-dummy, parallel-group, 12-week study in male and female patients, 12 years of age and older, with persistent asthma.
- Trial name
- NCT02031640
- Testing
- Beclomethasone dipropionate, Albuterol/salbutamol
- Where
- 131 sites in United States, Germany and 2 more
- Volunteers
- 1,113 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma
To demonstrate that CHF 1535 via NEXT DPI (beclomethasone dipropionate + formoterol fumarate 100 + 6 μg), 1 inhalation or 2 inhalations twice daily, for 12 weeks is non-inferior to the corresponding dose of CHF 1535 via HFA-134a…
- Trial name
- NCT00862394
- Testing
- BDP/Formoterol Next DPI, Foster
- Where
- Germany
- Volunteers
- 783 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen (0476-363)
The purpose of this study is to assess the treatment effect of montelukast 10mg on the primary endpoint of Asthma Control Questionnaire(ACQ), over a 8-week period, in persistent asthma patients with or without allergic rhinitis.
- Trial name
- STAR (NCT00445107)
- Testing
- MK0476, montelukast sodium / Duration of Treatment: 8 Weeks
- Volunteers
- 198 people
- Sponsor
- Organon and Co
Asthma
Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma
This study was designed to assess the safety of indacaterol (300 µg and 600 µg (2 x 300 μg capsules) once daily [od]), compared with salmeterol (50 μg twice a day [b.i.d.]), over 26 weeks, in patients with moderate to severe…
- Trial name
- NCT00529529
- Testing
- Indacaterol 300 μg, Salmeterol 50 μg
- Where
- 126 sites in United States, Argentina and 10 more
- Volunteers
- 805 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma
The objective of this study is to evaluate if single subcutaneous (SC) doses of PL-3994, administered to patients with asthma can achieve a clinically meaningful increase in pulmonary function (Forced Expiratory Volume in one…
- Trial name
- NCT01304628
- Testing
- PL-3994
- Where
- United States
- Sponsor
- Palatin Technologies, Inc
Asthma
CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids
A phase IIb study in patients to evaluate CYT003- QbG10 versus placebo, in patients with mild to moderate allergic asthma not sufficiently controlled on inhaled steroid.
- Trial name
- NCT02087644
- Testing
- CYT003
- Where
- United States
- Sponsor
- Cytos Biotechnology AG
Asthma
Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home
The purpose of the study is to assess functionality, performance, and reliability of an single-use auto-injector (AI) with benralizumab administered subcutaneously (SC) in an at-home setting reported by the patient or caregiver…
- Trial name
- GRECO (NCT02918071)
- Testing
- Benralizumab
- Where
- 25 sites in United States, Canada
- Volunteers
- 121 people
- Sponsor
- AstraZeneca
Chronic Asthma
The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388)
This study will test the safety and effectiveness of a range of doses of MK0476 (montelukast) compared to placebo on improved lung function in patients with chronic asthma.
- Trial name
- NCT00739297
- Testing
- Comparator: montelukast
- Volunteers
- 68 people
- Sponsor
- Organon and Co
Persistent Allergic Asthma
Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy
This study will assess the efficacy, safety and tolerability of omalizumab, compared to placebo in 18 to 75 year old Chinese patients with moderate to severe persistent allergic asthma who have inadequate asthma control despite…
- Trial name
- NCT01202903
- Testing
- Omalizumab
- Where
- 39 sites in China
- Volunteers
- 616 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
The purpose of this study is to determine the efficacy and safety of multiple CSJ117 doses (0.5; 1; 2; 4 and 8 mg) inhaled once daily compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult patients…
- Trial name
- NCT04410523
- Testing
- CSJ117
- Where
- 113 sites in United States, Argentina and 13 more
- Volunteers
- 335 people
- Sponsor
- Novartis Pharmaceuticals
Severe Asthma
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
This study aims to explore the potential for Tezepelumab-treated severe asthmatic patients to effectively and safely reduce their background maintenance medication while maintaining asthma symptom control.
- Trial name
- TAPER (NCT07363642)
- Testing
- Tezepelumab
- Where
- 75 sites in China
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Asthma
Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, Montelukast Sodium) for Acute Asthma (MK-0476-288)
The purpose of this study is to evaluate improved results of treatment for patients entering an emergency department with asthma attacks when given an investigational IV administration of an approved drug (MK-0476, montelukast…
- Trial name
- NCT00092989
- Testing
- montelukast sodium
- Volunteers
- 650 people
- Sponsor
- Organon and Co